A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy - PubMed (original) (raw)

Clinical Trial

doi: 10.1093/neuonc/nop015. Epub 2009 Dec 14.

Lauren E Abrey, Andrew B Lassman, Susan M Chang, Kathleen R Lamborn, John G Kuhn, W K Alfred Yung, Mark R Gilbert, Kenneth A Aldape, Patrick Y Wen, Howard A Fine, Minesh Mehta, Lisa M Deangelis, Frank Lieberman, Timothy F Cloughesy, H Ian Robins, Janet Dancey, Michael D Prados; North American Brain Tumor Consortium

Affiliations

Clinical Trial

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

Jeffrey J Raizer et al. Neuro Oncol. 2010 Jan.

Abstract

Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were eligible. Primary objective for recurrent MG was progression-free survival at 6 months (PFS-6) and overall survival at 12 months for NP GBM post-RT. Secondary objectives for recurrent MGs were response, survival, assessment of toxicity, and pharmacokinetics (PKs). Treatment with enzyme-inducing antiepileptic drugs was not allowed. Patients received 150 mg/day erlotinib. Patients requiring surgery were treated 7 days prior to tumor removal for PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR) and intracellular signaling pathways. Ninety-six patients were evaluable (53 recurrent MG and 43 NP GBM); 5 patients were not evaluable for response. PFS-6 in recurrent GBM was 3% with a median PFS of 2 months; PFS-6 in recurrent AG was 27% with a median PFS of 2 months. Twelve-month survival was 57% in NP GBMs post-RT. Primary toxicity was dermatologic. The tissue-to-plasma ratio normalized to nanograms per gram dry weight for erlotinib and OSI-420 ranged from 25% to 44% and 30% to 59%, respectively, for pretreated surgical patients. No effect on EGFR or intratumoral signaling was seen. Patients with NP GBM post-RT who developed rash in cycle 1 had improved survival (P < .001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT.

PubMed Disclaimer

Figures

Fig. 1.

Fig. 1.

Kaplan–Meier curves for recurrent GBMs for OS (upper curve) and PFS (lower curve).

Fig. 2.

Fig. 2.

Kaplan–Meier curves for recurrent AGs for OS (upper curve) and PFS (lower curve).

Fig. 3.

Fig. 3.

Kaplan–Meier curves NP GBMs post-RT for OS (upper curve) and PFS (lower curve).

Similar articles

Cited by

References

    1. DeAngelis LM. Chemotherapy for brain tumors—a new beginning. N Engl J Med. 2005;352:1036–1038. - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. - PubMed
    1. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996;56:5079–5086. - PubMed
    1. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 1994;91:7727–7731. - PMC - PubMed
    1. Rasheed BK, Wiltshire RN, Bigner SH, et al. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol. 1999;11:162–167. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources